Vacuum Cancer
Vacuum Cancer is developing the first implantable medical device designed to physically transform the tumor microenvironment in stage 3 and 4 solid cancers. The device aspirates necrotic and interstitial fluids and enables repeated, direct intratumoral injection of any drug type, aiming to make existing treatments less toxic and more efficient. The company is collaborating with oncology and medical device engineering specialists to refine the technology.
- Medical Devices
- Healthcare Technology
- Hardware
Funding
Founders
Founder details are not available yet.
Product
Problem
Patients with advanced solid cancers (stage 3 and 4) often have very limited treatment options, and existing approaches frequently fail to deliver therapeutic agents effectively into the tumor microenvironment. The inability to repeatedly and efficiently inject drugs directly into tumors hampers treatment efficacy and patient outcomes.
Solution
Vacuum Cancer is developing the first implantable medical device designed to aspirate tumor interstitial fluid and inject drugs directly into the tumor. This device enables repeated and fast intratumoral drug injections, transforming the tumor microenvironment to improve treatment efficiency. The approach is intended to create a new standard of care for advanced cancer patients by overcoming barriers to direct drug delivery. The company is collaborating with experts in cancer treatment, medical device engineering, and R&D to refine the technology, with more technical details expected in the coming months.
Target Audience
Healthcare professionals treating advanced solid cancer patients, as well as drug developers and potential partners interested in improving intratumoral therapy delivery.
Features
- Implantable medical device capable of aspirating necrotic and interstitial fluids from the tumor microenvironment
- Direct intratumoral drug injection capability supporting repeated use and any type of drug
- Designed specifically for stage 3 and stage 4 solid tumor treatment
- Physical mechanism of action intended to stop cancer progression while reducing toxicity of existing treatments
- Developed in collaboration with specialists in oncology and medical device R&D